Komori
TAUNS Laboratories (197A) · InitiativeAdvanced

IP and Technology Partnership Investments Toward the 10-Year Business Vision

First written in FY2024. 8 of 9 entries say "Advanced", first in FY2025. Latest entry: FY2026.

9entries
3years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025 – FY20262024: 120242025: 120252026: 72026
Same theme, other companies

The whole theme swung hardest in 2021: 2 of 9 companies on the "Worse" side.

17 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 42 companies compared. The sentences above are computed from all 42.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Investment securities include shares of ElectraDX,Inc. acquired in November 2025 for the purpose of a business alliance aimed at increasing enterprise value, recognized at ¥1,187.668 million.」

    Following the previous investment in アイリス株式会社 and other entities, the acquisition of ElectraDX,Inc. shares in November 2025 was specified as an investment for the purpose of a business alliance.
  2. FY2025AdvancedAnnual report

    「Investment securities include ¥2,000.005 million in shares of Iris Co., Ltd., acquired in April 2025 for the purpose of a business alliance to enhance corporate value.」

    The policy of investing in intellectual property and technology partners took concrete form through investments for business alliances, including the acquisition of shares in Iris Co., Ltd. in April 2025. Investment securities increased from approximately ¥30 million in the previous fiscal year to approximately ¥4.18 billion, including four unlisted shares acquired for business alliance purposes.
  3. FY2024First statedAnnual report

    「By comparing our 10-year vision with our current technology base, we will make strategic investments in intellectual property and equity investments in technology partners, focusing on areas where we are lacking or need to strengthen our capabilities.」

    The company plans to make investments in intellectual property and equity investments in technology partners based on gaps relative to its future vision.
Moved together

"Development of New Core Technologies and an Inspection Platform" moved the same way as this thread, in the same document, in 5 of its 9 moves.

553332★123456
  1. ★This thread
  2. 1Development of New Core Technologies and an Inspection Platform5×
  3. 2Expansion into non-infectious disease areas, including chronic diseases, cancer and kidney disease5×
  4. 3High-sensitivity, multi-analyte, quantitative POCT enabled by D-IA3×
  5. 4Clinical testing contract services provided by タウンズクリニカルラボ3×
  6. 5Productivity Gains Through a New Core Business System and Medical Data Platform3×
  7. 6Overseas Expansion Through Distributor Networks, Overseas-Market Products and High-Value-Added Products2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet. It last moved in the Business Alliance of 2026-08-20: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
IP and Technology Partnership Investments Toward the 10-Year Business Vision | TAUNS Laboratories,Inc. (197A) | Komori